EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Meropenem-Vaborbactam Activity against U.S. Multidrug-Resistant Enterobacterales Strains, Including Carbapenem-Resistant Isolates

Dee Shortridge iD, Valerie Kantro iD, Mariana Castanheira iD

Microbiology Spectrum · 14.02.2023 · 11 (1)

DOI: 10.1128/spectrum.04507-22 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Microbiology Spectrum, erschienen am 14.02.2023. Verfasst von Dee Shortridge und 2 weiteren Autor:innen. Beteiligte Einrichtung: JMI Laboratories, North Liberty, Iowa, USA. Hauptthemen laut MEDLINE: Carbapenems, Gammaproteobacteria. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Melinta Therapeutics.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Carbapenems are a common first-line therapy for serious Gram-negative infections, but CRE isolates have become an urgent health concern. Meropenem-vaborbactam is a combination of the carbapenem meropenem and vaborbactam, which is a β-lactamase inhibitor with activity against serine carbapenemases, including KPC-producing isolates.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CarbapenemsGammaproteobacteriaUnited StatesMeropenemAnti-Bacterial Agentsbeta-Lactamase InhibitorsBacterial ProteinsImipenembeta-LactamasesGram-Negative BacteriaSerineMicrobial Sensitivity TestsBoronic AcidsDrug CombinationsHeterocyclic Compounds, 1-Ring

Stichwörter der Autor:innen

CREU.S. surveillancemeropenem-vaborbactamsurveillance studies

Substanzen

MeropenemCarbapenemsAnti-Bacterial Agentsbeta-Lactamase InhibitorsBacterial ProteinsImipenembeta-LactamasesSerinemeropenem and vaborbactamBoronic Acids

Autor:innen und Institutionen

  • JMI Laboratories, North Liberty, Iowa, USA.

ORCID-Profile: Dee Shortridge, Valerie Kantro, Mariana Castanheira

Förderung

  • Melinta Therapeutics

Zitieren

APA

Shortridge, D., Kantro, V., & Castanheira, M. (2023). Meropenem-Vaborbactam Activity against U.S. Multidrug-Resistant Enterobacterales Strains, Including Carbapenem-Resistant Isolates. Microbiology Spectrum, 11(1). https://doi.org/10.1128/spectrum.04507-22

Vancouver

Shortridge D, Kantro V, Castanheira M. Meropenem-Vaborbactam Activity against U.S. Multidrug-Resistant Enterobacterales Strains, Including Carbapenem-Resistant Isolates. Microbiology Spectrum. 2023;11(1). doi:10.1128/spectrum.04507-22

BibTeX
@article{Shortridge2023,
  author = {Shortridge, Dee and Kantro, Valerie and Castanheira, Mariana},
  title = {Meropenem-Vaborbactam Activity against U.S. Multidrug-Resistant Enterobacterales Strains, Including Carbapenem-Resistant Isolates},
  journal = {Microbiology Spectrum},
  year = {2023},
  volume = {11},
  number = {1},
  doi = {10.1128/spectrum.04507-22}
}
Kostenlos starten →